Merck & Company (MRK)

$128.58 +0.21 (0.16%)
Market Cap 317.57B
Revenue (ttm) 65.01B
Net Income (ttm) 18.25B
EPS (ttm) N/A
PE Ratio 39.99
Forward PE 46.30
Profit Margin 28.08%
Debt to Equity Ratio 1.02
Volume 7,347,500
Avg Vol 10,598,900
Day's Range N/A - N/A
Shares Out 2.47B
Stochastic %K 27%
Beta 0.19
Analysts Strong Sell
Price Target $137.04

Company Profile

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health manageme...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 908 740 4000
Address:
126 East Lincoln Avenue, Rahway, United States
ETAlpha
ETAlpha Aug. 9 at 7:36 PM
$MRK is trading strong around $112.50 right now! My scanner just flagged a massive breakout setup on $MRK, forming a textbook cup and handle pattern. True market pros don't chase hype we hunt for high-probability technical continuation patterns before the crowd wakes up! With a massive breakout looming, avoid chasing green highs blindly and scale into key support dips!
0 · Reply
Game_Day
Game_Day Aug. 9 at 5:06 PM
FRIDAY AUG 7 🔥 I am down on ebay because I took lotto calls instead of holding the golden alert yesterday that reached 75-100%+ Thats ok. This day was is blessed and definitely needed. Important to stick with your system and not shift from it. Love what I do love you all see you soon with a new alert $MRK todays options $XLV BOSS alert healthcare ETF NEAR $7K with $CLRO AH $WPM $AEM New watch list posting tomorrow early am 💰
0 · Reply
StockNavigator_
StockNavigator_ Aug. 9 at 3:26 PM
How Every Dow Jones Stock Has Performed in 2026 📊 （Part 2） The strength continues beyond the names from Part 1: $KO +24.5% 🟢 $UNH +23.3% 🟢 $CVX +22.4% 🟢 $MRK +22.2% 🟢 $HON +20.4% 🟢 A pretty broad mix of consumer, healthcare, energy and industrial names are showing solid gains this year. I’m watching to see which names can keep the momentum and which ones start to lag. The next signal is coming. Turn on notifications so you don't miss the next opportunity.
0 · Reply
EquityVoyager_1
EquityVoyager_1 Aug. 9 at 2:22 PM
DOW 2026 LEADERS ARE STACKING GAINS Here are five Dow names showing serious strength so far this year: $KO +24.5% $UNH +23.3% $CVX +22.4% $MRK +22.2% $HON +20.4% Defensive giants are quietly putting up some impressive numbers. Which one has the best setup from here? If you would like to learn more about marketing strategies, please visit my personal webpage.
0 · Reply
Mike22332233
Mike22332233 Aug. 9 at 12:18 PM
$SLS OK ... # 6 Someone asked for my top 10 Special Situation Stock holdings .... I've called $SLS the best asymmetrical investment I've found in my 43 years of investing ... It's the largest holding, by far, in an over $1.35 mil portfolio ... I expect MINIMUM BO of $140 and MAXIMUM BO price of $202 in a Bidding War during Q4! Now #6 ... $INBX ... The interim Phase 2 data for INBRX-106 + KEYTRUDA combination was outstanding and achieved a cORR of 44.0% vs. 21.4% with KEYTRUDA alone ... Patents on MRK's $34 Bil a yr KEYTRUDA franchise will soon run out, but MRK can salvage that franchise, and re-start that patent clock!! .... $MRK will Buy INBRX-106 from INBX .... I just don't know if it will be for $3.5 B ($240/shr) or $7 B ($480) ... and I don't know if it's in 2 months or 6 months !! ... and you will still own the rest of INBX, which is worth just as much -- INBX has done spinoff deals like this in the past !! FOLLOW me 👉 @Mike22332233 for other HUGE profit stocks
2 · Reply
BioTechHealthX
BioTechHealthX Aug. 9 at 2:47 AM
$GILD $ABT $DHR $LLY $MRK Analysts see meaningful upside in several top healthcare stocks for 2026, with one biotech leader offering nearly 30% implied upside based on the analyst target and supplied market price. https://biotechhealthx.com/biotech-news/top-5-healthcare-stocks-to-buy-with-1000-in-2026/
0 · Reply
clan
clan Aug. 8 at 10:44 AM
$MNKD ❔️ The question is not, "What is Mannkind?" The answer to, "Who is Mannkind?" is ... It's a conglomerate of support networks, advocates, and partnerships, successfully working together to bring medical solutions to patients, young and old, so they may live life more humann. $IBB $MRK $AMGN
0 · Reply
Lowkeyoptions
Lowkeyoptions Aug. 8 at 1:21 AM
$KPTI $MRK $ESAIY https://finance.yahoo.com/healthcare/articles/endometrial-cancer-market-share-analysis-093700652.html Endometrial Cancer Market Share Analysis and Industry Trends (2026-2031) Featuring Merck, Eisai, Karyopharm Therapeutics, Context Therapeutics, Seagen and More Global Endometrial Cancer Market Forecast to Reach USD 40.66 Billion by 2031 The global endometrial cancer market is projected to expand from USD 30.60 billion in 2025 to USD 32.09 billion in 2026. By 2031, the market is forecast to reach USD 40.66 billion, registering a compound annual growth rate (CAGR) of 4.86% from 2026 to 2031. Growth is being supported by rising disease prevalence, an ageing female population, increasing obesity rates,
0 · Reply
JackCampbell
JackCampbell Aug. 7 at 4:46 PM
$CTXR while LYMPHIR is demonstrating strong performance in CTCL as seen in its commercial launch, its true potential lies in combination therapies, where it could completely disrupt CAR-T and T-Regs treatments. $MRK $GILD
2 · Reply
fda_tracker
fda_tracker Aug. 7 at 2:59 PM
$MRK New PDUFA Date 2027-03-22 MERCK & CO., INC. Link: https://www.businesswire.com/news/home/20260805331090/en/U.S.-FDA-Accepts-sBLA-for-ENFLONSIA-clesrovimab-cfor-to-Update-its-Respiratory-Syncytial-Virus-RSV-Lower-Respiratory-Tract-Disease-Indication-to-Include-Children-Under-Two-Years-at-Increased-Risk-for-Severe-RSV-for-Their-Second-Season Calendar: http://www.fdatracker.com/fda-calendar/
0 · Reply
Latest News on MRK
These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks

Aug 7, 2026, 1:15 AM EDT - 2 days ago

These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks

IBB IHE MRNA PJP SMMT XBI

Merck says FDA accepts sBLA for enflonsia

2026-08-06T12:11:53.000Z - 3 days ago

Merck says FDA accepts sBLA for enflonsia

U.S. FDA Accepts sBLA for ENFLONSIA™ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second Season

Aug 6, 2026, 6:45 AM EDT - 3 days ago

U.S. FDA Accepts sBLA for ENFLONSIA™ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second Season

Merck announces Health Canada approval of KEYTRUDA for adults with MIBC

2026-08-05T15:05:33.000Z - 4 days ago

Merck announces Health Canada approval of KEYTRUDA for adults with MIBC

PFE

Merck price target raised to $116 from $113 at Morgan Stanley

2026-08-05T14:10:13.000Z - 4 days ago

Merck price target raised to $116 from $113 at Morgan Stanley

Merck price target raised to $146 from $145 at Guggenheim

2026-08-05T11:28:42.000Z - 4 days ago

Merck price target raised to $146 from $145 at Guggenheim

Merck & Co. Earnings Call Transcript: Q2 2026

Aug 4, 2026, 9:00 AM EDT - 5 days ago

Merck & Co. Earnings Call Transcript: Q2 2026

Merck & Co. Earnings release: Q2 2026

Aug 4, 2026, 9:00 AM EDT - 5 days ago

Merck & Co. Earnings release: Q2 2026

Merck & Co. Slides: Q2 2026

Aug 4, 2026, 9:00 AM EDT - 5 days ago

Merck & Co. Slides: Q2 2026

Merck & Co. Quarterly report: Q2 2026

Aug 4, 2026, 9:00 AM EDT - 5 days ago

Merck & Co. Quarterly report: Q2 2026

Merck Cuts Full-Year Profit Forecast as Acquisition Costs Weigh on Bottom Line

Aug 4, 2026, 6:41 AM EDT - 5 days ago

Merck Cuts Full-Year Profit Forecast as Acquisition Costs Weigh on Bottom Line

Merck posts better-than-expected second-quarter results on Keytruda strength

Aug 4, 2026, 6:35 AM EDT - 5 days ago

Merck posts better-than-expected second-quarter results on Keytruda strength

Merck hikes revenue outlook as new drug sales grow, but cuts profit guidance due to deal charges

Aug 4, 2026, 6:34 AM EDT - 5 days ago

Merck hikes revenue outlook as new drug sales grow, but cuts profit guidance due to deal charges

Merck Delivers a Clean Earnings Beat on Oncology Strength. Is It Enough to Impress Wall Street?

Aug 4, 2026, 6:30 AM EDT - 5 days ago

Merck Delivers a Clean Earnings Beat on Oncology Strength. Is It Enough to Impress Wall Street?

Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline

Aug 4, 2026, 6:30 AM EDT - 5 days ago

Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline

Merck & Co. Transcript: Investor update

Aug 3, 2026, 8:00 AM EDT - 6 days ago

Merck & Co. Transcript: Investor update

Merck & Co. Slides: Investor update

Aug 3, 2026, 8:00 AM EDT - 6 days ago

Merck & Co. Slides: Investor update

Merck, Wellcome partner with global health group to make Ebola vaccine for clinical trials

Jul 30, 2026, 1:09 AM EDT - 10 days ago

Merck, Wellcome partner with global health group to make Ebola vaccine for clinical trials

Merck Announces Fourth-Quarter 2026 Dividend

Jul 29, 2026, 11:04 AM EDT - 11 days ago

Merck Announces Fourth-Quarter 2026 Dividend

Merck price target raised to $150 from $140 at Barclays

2026-07-29T09:10:33.000Z - 11 days ago

Merck price target raised to $150 from $140 at Barclays

Merck announces initial access plans for alimatravir

2026-07-24T10:51:09.000Z - 16 days ago

Merck announces initial access plans for alimatravir

Merck licenses experimental HIV pill to generic makers in 129 countries

Jul 24, 2026, 6:48 AM EDT - 16 days ago

Merck licenses experimental HIV pill to generic makers in 129 countries

Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development

Jul 24, 2026, 6:45 AM EDT - 16 days ago

Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development

Gilead, Merck weekly HIV pill keeps virus suppressed in late-stage trials

Jul 21, 2026, 1:27 PM EDT - 19 days ago

Gilead, Merck weekly HIV pill keeps virus suppressed in late-stage trials

GILD

Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy

Jul 21, 2026, 10:00 AM EDT - 19 days ago

Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy

GILD

What Comes After Merck's Keytruda? The Race for the Next Standard Cancer Treatment.

Jul 20, 2026, 2:00 AM EDT - 20 days ago

What Comes After Merck's Keytruda? The Race for the Next Standard Cancer Treatment.

Use These ETFs as Health Stocks LLY, UNH, MRK Thrive

Jul 17, 2026, 8:46 AM EDT - 23 days ago

Use These ETFs as Health Stocks LLY, UNH, MRK Thrive

LLY UNH PPH VHT XLV

New Cholesterol Pill, Earnings Growth Boost Merck Shares

Jul 17, 2026, 8:40 AM EDT - 23 days ago

New Cholesterol Pill, Earnings Growth Boost Merck Shares

Why Healthcare Stocks Look Like a Haven in This Market

Jul 16, 2026, 5:07 PM EDT - 24 days ago

Why Healthcare Stocks Look Like a Haven in This Market

XLV

FDA signs off on Merck's cholesterol-lowering pill — the first oral treatment of its kind

Jul 16, 2026, 2:14 PM EDT - 24 days ago

FDA signs off on Merck's cholesterol-lowering pill — the first oral treatment of its kind

Merck's cholesterol pill gets US FDA approval

Jul 16, 2026, 6:49 AM EDT - 24 days ago

Merck's cholesterol pill gets US FDA approval

The FDA approved Lipfendra, a first-of-its kind pill from Merck that is designed to help lower cholesterol levels beyond what statins alone can achieve

Jul 16, 2026, 6:45 AM EDT - 24 days ago

The FDA approved Lipfendra, a first-of-its kind pill from Merck that is designed to help lower cholesterol levels beyond what statins alone can achieve

Merck Gets Approval for Powerful Cholesterol-Cutting Pill

Jul 16, 2026, 6:45 AM EDT - 24 days ago

Merck Gets Approval for Powerful Cholesterol-Cutting Pill

Merck's LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia

Jul 16, 2026, 6:45 AM EDT - 24 days ago

Merck's LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia

Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026

Jul 15, 2026, 7:00 AM EDT - 25 days ago

Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

Jul 10, 2026, 2:10 PM EDT - 4 weeks ago

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4

Jul 1, 2026, 6:45 AM EDT - 5 weeks ago

Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4

US House committee opens investigation into Merck, AbbVie China drug trials

Jun 30, 2026, 6:02 AM EDT - 5 weeks ago

US House committee opens investigation into Merck, AbbVie China drug trials

ABBV

Merck & Company (MRK) Price Forecast: Can Momentum Drive New Highs?

Jun 29, 2026, 5:08 PM EDT - 5 weeks ago

Merck & Company (MRK) Price Forecast: Can Momentum Drive New Highs?

Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV

Jun 29, 2026, 6:45 AM EDT - 5 weeks ago

Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV

The Big 3: JPM, DHR, MRK

Jun 25, 2026, 1:00 PM EDT - 6 weeks ago

The Big 3: JPM, DHR, MRK

DHR JPM

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)

Jun 25, 2026, 6:45 AM EDT - 6 weeks ago

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)

European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer

Jun 24, 2026, 6:45 AM EDT - 6 weeks ago

European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer

Merck and Mae Partner to Expand Doula Workforce and Address Maternal Health Disparities in High-Risk U.S. Markets

Jun 23, 2026, 10:00 AM EDT - 6 weeks ago

Merck and Mae Partner to Expand Doula Workforce and Address Maternal Health Disparities in High-Risk U.S. Markets

Merck's bowel disease drug meets main goal in late-stage trial

Jun 22, 2026, 7:16 AM EDT - 6 weeks ago

Merck's bowel disease drug meets main goal in late-stage trial

Merck's Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

Jun 22, 2026, 6:45 AM EDT - 6 weeks ago

Merck's Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

Merck's pneumococcal vaccine wins US approval for high-risk children, teens

Jun 18, 2026, 6:45 AM EDT - 7 weeks ago

Merck's pneumococcal vaccine wins US approval for high-risk children, teens

U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease

Jun 18, 2026, 6:45 AM EDT - 7 weeks ago

U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease

Study Reveals Dog Owners and Veterinarians See Challenges in Treating Allergic Skin Disease, Highlighting a Need for a Targeted Rapid Onset Treatment for Dogs of All Ages

Jun 17, 2026, 6:45 AM EDT - 7 weeks ago

Study Reveals Dog Owners and Veterinarians See Challenges in Treating Allergic Skin Disease, Highlighting a Need for a Targeted Rapid Onset Treatment for Dogs of All Ages

Protillion Biosciences Announces Drug Discovery Collaboration with Merck

Jun 16, 2026, 8:00 AM EDT - 7 weeks ago

Protillion Biosciences Announces Drug Discovery Collaboration with Merck

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Cell Renal Cell Carcinoma (ccRCC)

Jun 12, 2026, 4:10 PM EDT - 2 months ago

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Cell Renal Cell Carcinoma (ccRCC)

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

Jun 11, 2026, 7:14 AM EDT - 2 months ago

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

ABBV ALKS AMGN GILD IBB IHE JNJ

Merck Animal Health to Acquire TARGAN

Jun 11, 2026, 6:45 AM EDT - 2 months ago

Merck Animal Health to Acquire TARGAN

Merck & Co. Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 11:20 AM EDT - 2 months ago

Merck & Co. Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

Jun 9, 2026, 9:20 AM EDT - 2 months ago

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

AMGN JNJ LLY NVO PFE

The space race is coming for pharma: Why drug development is heading to lower Earth orbit

Jun 9, 2026, 3:20 AM EDT - 2 months ago

The space race is coming for pharma: Why drug development is heading to lower Earth orbit

BMY LLY PFE RDW UTHR XBI

Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment

Jun 8, 2026, 4:35 PM EDT - 2 months ago

Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment

GILD

Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study

Jun 8, 2026, 4:30 PM EDT - 2 months ago

Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study

GILD

Rejuvenate Bio Announces $6 Million Financing and Strategic R&D Collaboration with Merck Animal Health

Jun 8, 2026, 8:00 AM EDT - 2 months ago

Rejuvenate Bio Announces $6 Million Financing and Strategic R&D Collaboration with Merck Animal Health

Merck & Co. Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 10:30 AM EDT - 2 months ago

Merck & Co. Transcript: Jefferies Global Healthcare Conference 2026

Merck to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Jun 2, 2026, 6:45 AM EDT - 2 months ago

Merck to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Merck & Co. Transcript: Investor update

Jun 1, 2026, 7:00 PM EDT - 2 months ago

Merck & Co. Transcript: Investor update

Merck & Co. Press release: Investor update

Jun 1, 2026, 7:00 PM EDT - 2 months ago

Merck & Co. Press release: Investor update

Merck & Co. Slides: Investor update

Jun 1, 2026, 7:00 PM EDT - 2 months ago

Merck & Co. Slides: Investor update

Merck exec says company is discussing use of COVID antiviral drug in Ebola response

Jun 1, 2026, 12:55 PM EDT - 2 months ago

Merck exec says company is discussing use of COVID antiviral drug in Ebola response

Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting

Jun 1, 2026, 8:00 AM EDT - 2 months ago

Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting

MRNA

FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)

May 29, 2026, 6:45 AM EDT - 2 months ago

FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)

ETAlpha
ETAlpha Aug. 9 at 7:36 PM
$MRK is trading strong around $112.50 right now! My scanner just flagged a massive breakout setup on $MRK, forming a textbook cup and handle pattern. True market pros don't chase hype we hunt for high-probability technical continuation patterns before the crowd wakes up! With a massive breakout looming, avoid chasing green highs blindly and scale into key support dips!
0 · Reply
Game_Day
Game_Day Aug. 9 at 5:06 PM
FRIDAY AUG 7 🔥 I am down on ebay because I took lotto calls instead of holding the golden alert yesterday that reached 75-100%+ Thats ok. This day was is blessed and definitely needed. Important to stick with your system and not shift from it. Love what I do love you all see you soon with a new alert $MRK todays options $XLV BOSS alert healthcare ETF NEAR $7K with $CLRO AH $WPM $AEM New watch list posting tomorrow early am 💰
0 · Reply
StockNavigator_
StockNavigator_ Aug. 9 at 3:26 PM
How Every Dow Jones Stock Has Performed in 2026 📊 （Part 2） The strength continues beyond the names from Part 1: $KO +24.5% 🟢 $UNH +23.3% 🟢 $CVX +22.4% 🟢 $MRK +22.2% 🟢 $HON +20.4% 🟢 A pretty broad mix of consumer, healthcare, energy and industrial names are showing solid gains this year. I’m watching to see which names can keep the momentum and which ones start to lag. The next signal is coming. Turn on notifications so you don't miss the next opportunity.
0 · Reply
EquityVoyager_1
EquityVoyager_1 Aug. 9 at 2:22 PM
DOW 2026 LEADERS ARE STACKING GAINS Here are five Dow names showing serious strength so far this year: $KO +24.5% $UNH +23.3% $CVX +22.4% $MRK +22.2% $HON +20.4% Defensive giants are quietly putting up some impressive numbers. Which one has the best setup from here? If you would like to learn more about marketing strategies, please visit my personal webpage.
0 · Reply
Mike22332233
Mike22332233 Aug. 9 at 12:18 PM
$SLS OK ... # 6 Someone asked for my top 10 Special Situation Stock holdings .... I've called $SLS the best asymmetrical investment I've found in my 43 years of investing ... It's the largest holding, by far, in an over $1.35 mil portfolio ... I expect MINIMUM BO of $140 and MAXIMUM BO price of $202 in a Bidding War during Q4! Now #6 ... $INBX ... The interim Phase 2 data for INBRX-106 + KEYTRUDA combination was outstanding and achieved a cORR of 44.0% vs. 21.4% with KEYTRUDA alone ... Patents on MRK's $34 Bil a yr KEYTRUDA franchise will soon run out, but MRK can salvage that franchise, and re-start that patent clock!! .... $MRK will Buy INBRX-106 from INBX .... I just don't know if it will be for $3.5 B ($240/shr) or $7 B ($480) ... and I don't know if it's in 2 months or 6 months !! ... and you will still own the rest of INBX, which is worth just as much -- INBX has done spinoff deals like this in the past !! FOLLOW me 👉 @Mike22332233 for other HUGE profit stocks
2 · Reply
BioTechHealthX
BioTechHealthX Aug. 9 at 2:47 AM
$GILD $ABT $DHR $LLY $MRK Analysts see meaningful upside in several top healthcare stocks for 2026, with one biotech leader offering nearly 30% implied upside based on the analyst target and supplied market price. https://biotechhealthx.com/biotech-news/top-5-healthcare-stocks-to-buy-with-1000-in-2026/
0 · Reply
clan
clan Aug. 8 at 10:44 AM
$MNKD ❔️ The question is not, "What is Mannkind?" The answer to, "Who is Mannkind?" is ... It's a conglomerate of support networks, advocates, and partnerships, successfully working together to bring medical solutions to patients, young and old, so they may live life more humann. $IBB $MRK $AMGN
0 · Reply
Lowkeyoptions
Lowkeyoptions Aug. 8 at 1:21 AM
$KPTI $MRK $ESAIY https://finance.yahoo.com/healthcare/articles/endometrial-cancer-market-share-analysis-093700652.html Endometrial Cancer Market Share Analysis and Industry Trends (2026-2031) Featuring Merck, Eisai, Karyopharm Therapeutics, Context Therapeutics, Seagen and More Global Endometrial Cancer Market Forecast to Reach USD 40.66 Billion by 2031 The global endometrial cancer market is projected to expand from USD 30.60 billion in 2025 to USD 32.09 billion in 2026. By 2031, the market is forecast to reach USD 40.66 billion, registering a compound annual growth rate (CAGR) of 4.86% from 2026 to 2031. Growth is being supported by rising disease prevalence, an ageing female population, increasing obesity rates,
0 · Reply
JackCampbell
JackCampbell Aug. 7 at 4:46 PM
$CTXR while LYMPHIR is demonstrating strong performance in CTCL as seen in its commercial launch, its true potential lies in combination therapies, where it could completely disrupt CAR-T and T-Regs treatments. $MRK $GILD
2 · Reply
fda_tracker
fda_tracker Aug. 7 at 2:59 PM
$MRK New PDUFA Date 2027-03-22 MERCK & CO., INC. Link: https://www.businesswire.com/news/home/20260805331090/en/U.S.-FDA-Accepts-sBLA-for-ENFLONSIA-clesrovimab-cfor-to-Update-its-Respiratory-Syncytial-Virus-RSV-Lower-Respiratory-Tract-Disease-Indication-to-Include-Children-Under-Two-Years-at-Increased-Risk-for-Severe-RSV-for-Their-Second-Season Calendar: http://www.fdatracker.com/fda-calendar/
0 · Reply
HedgeFollow
HedgeFollow Aug. 7 at 2:35 PM
_ _ _ _ 🔍 𝗡𝗘𝗪 13𝗙 𝗥𝗘𝗟𝗘𝗔𝗦𝗘𝗗 🔎 5-star Hedge Fund Manager Ken Fisher just filed his 13F for last quarter. Some of his most notable position changes... 𝗡𝗲𝘄 𝗕𝘂𝘆𝘀: $GE, $PANW 𝗔𝗱𝗱𝗲𝗱 𝗺𝗼𝗿𝗲: $MRK 𝗥𝗲𝗱𝘂𝗰𝗲𝗱: $COP 𝗗𝗢𝗨𝗕𝗟𝗘𝗗: $CSCO Ken's 𝗽𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼 𝗶𝘀 𝗨𝗣 95.13% in the past 3 years. Source: hedgefollow.com/funds/Fisher+Asset+Management
0 · Reply
Quantumup
Quantumup Aug. 7 at 10:42 AM
Raymond James⬆️ $TRVI's PT to $40 from $27 and keeps at a Strong Buy after adding the non-IPF ILD indication to its model (70% PoS, $1.16B peak unadj'd sales in '35—⬆️its assumption for WAC pricing of Haduvio. $RHHBY VRNA - $MRK 𝑮̶𝑺̶𝑲̶ Here's what Raymond James said in its note to investors: https://x.com/Quantumup1/status/2085677838485606488?s=20
0 · Reply
kFella
kFella Aug. 6 at 3:46 PM
$XERS disappointing ER. No news, more delays, vague Q&A. Fairly valued at $1.3B with $400M rev + $100M cash. Only hopium is comment on holding phase 3 Levo until commercial ready. Reminds of earlier $MRK collab contingent on full manufacturing and commercial plan.
0 · Reply
parcha
parcha Aug. 6 at 3:18 PM
Jim Cramer's top 10 things to watch in the stock market Thursday $LLY $JNJ $MRK $ABBV Bunch of price target hikes for Eli Lilly after another beat-and-raise quarter yesterday. Morgan Stanley, BMO and Wells Fargo all raised. So did Leerink, which touted Lilly’s improving profitability and next-generation obesity drugs. Retatrutide is the one I’m most interested in. Lilly is still my No. 1 pharma stock, followed by fellow Club name Johnson & Johnson. I also like Abbvie and Merck. https://www.cnbc.com/2026/08/06/jim-cramers-top-10-things-to-watch-in-the-stock-market-thursday.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension
0 · Reply
STP_TRADES
STP_TRADES Aug. 6 at 2:27 PM
ADDED 1000 MORE CONTRACTS 8/7 $MRK 135c @​.11 THIS CAN GO 20X
0 · Reply
VeltrixCapitalOfficial
VeltrixCapitalOfficial Aug. 6 at 2:21 PM
🚨 8/7 $MRK 135c @.11 1000 CONTRACTS
0 · Reply
scdtrader213
scdtrader213 Aug. 6 at 1:31 PM
$MRK moving towards 135
0 · Reply
Quantumup
Quantumup Aug. 6 at 12:02 PM
Guggenheim⬆️Best Idea $RVMD's PT to $240 while keeping at a Buy rating after RVMD announced 2Q26 earnings and provided a comprehensive pipeline update. $MRK $IMRX ERAS BBOT TNGX ANL VSTM Here's what Guggenheim said in its note to investors: https://x.com/Quantumup1/status/2085335584709431642?s=20
0 · Reply
focafoca99
focafoca99 Aug. 6 at 11:00 AM
$MRK expanded ENFLONSIA's RSV indication to include children under two for a second season, after FDA sBLA acceptance. https://www.rapidticker.com/news/mrk-us-fda-accepts-sbla-for-7f96d7
0 · Reply
IndyOne
IndyOne Aug. 6 at 10:44 AM
$MRNA In a statement after hours, vaccine maker Moderna said its “mFLUSIVA” vaccine against seasonal influenza has been approved for use by all adults aged 50 and older. The approval was based on a phase 3 trial involving nearly 41,000 people aged between 50-64 years, which found that the mRNA vaccine is around 26.6% more effective in preventing a flu infection compared to older flu shots. In June, the FDA’s independent vaccine advisory committee unanimously recommended the approval of the vaccine for adults aged between 50 and 64. The FDA has also granted accelerated approval for administering the vaccine to adults who are 65 and older, based on the panel’s recommendation—which could become a full approval if follow-up trial results are considered favorable. $MRK
1 · Reply
DefenseMania
DefenseMania Aug. 6 at 4:18 AM
Insane 1 BILLION ! !!! $PFE $ABBV $MRK easy $500 EOY https://finance.yahoo.com/m/833810e3-249c-3de2-ad32-7efb604e1a76/amgen-hikes-sales-outlook-by.html
1 · Reply
ILuvbiotech
ILuvbiotech Aug. 5 at 6:52 PM
$MRK you guys reckon a partnership is incoming or buy out for $NWBO ?
5 · Reply